Physician profile
Robert Lagrone
NPI 1417903378
$17,094.46
in general payments reported to CMS, 2019-2025
27 companies · $2,323 in 2025
The $2,323 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,443 · 2020: $4,508 · 2021: $1,675 · 2022: $1,754 · 2023: $1,980 · 2024: $2,413 · 2025: $2,323.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,493 · Education: $222.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,492.93 |
| Education | $221.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $3,027.90 | 2020-2025 | Benlysta |
| Amgen INC. | $2,777.36 | 2019-2025 | Enbrel, Tavneos, Otezla |
| Janssen Biotech, INC. | $2,397.26 | 2019-2025 | Tremfya, Simponi Aria, Remicade |
| Ucb, INC. | $1,925.37 | 2019-2025 | Cimzia, Bimzelx |
| Abbvie INC. | $1,772.66 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $1,332.75 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $738.56 | 2021-2025 | Saphnelo |
| Lilly USA, LLC | $733.69 | 2019-2024 | Taltz |
| Pfizer INC. | $480.82 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $417.41 | 2019-2025 | Orencia |
| Fresenius Kabi USA, LLC | $409.19 | 2023-2025 | Tyenne |
| Boehringer Ingelheim Pharmaceuticals, INC. | $249.39 | 2021-2025 | Ofev, Cyltezo, Spevigo |
| Sandoz INC. | $162.31 | 2023-2025 | Hyrimoz |
| Organon LLC | $143.97 | 2022-2025 | Hadlima, Renflexis, Nexplanon |
| Horizon Therapeutics Plc | $108.04 | 2020-2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $105.25 | 2021-2025 | |
| Sobi, INC | $81.58 | 2023-2024 | |
| Genentech USA, INC. | $61.91 | 2019-2024 | Actemra |
| Aurinia Pharma U.S., INC. | $57.49 | 2021-2022 | |
| Ultragenyx Pharmaceutical INC. | $45.52 | 2022-2024 | Crysvita |
| Regeneron Healthcare Solutions, INC. | $22.15 | 2019 | |
| Alexion Pharmaceuticals, INC. | $17.09 | 2025 | Strensiq |
| Takeda Pharmaceuticals U.S.A., INC. | $15.10 | 2021 | |
| Idorsia Pharmaceuticals US INC | $11.69 | 2022 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Lagrone listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.